Upgrade to SI Premium - Free Trial

Oppenheimer Reiterates Perform Rating on Editas Medicine (EDIT)

November 5, 2024 12:43 PM
Oppenheimer analyst Jay Olson reiterated a Perform rating on Editas Medicine (NASDAQ: EDIT).The analyst commented: "EDIT reported 3Q24 OpEx of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles